|
✨Day 1 at ADLM 2026 (formerly AACC) has set an incredible tone for the future of IVD. At our booth, the momentum was palpable. We welcomed an unprecedented flow of visitors from North America, Latin America, Europe, and Oceania—including lab directors, distributors, and procurement leaders. As a dual-certified member of ICSH and IFCC, URIT demonstrated how independent R&D can translate into tangible clinical value.
But beyond the foot traffic, what truly excited us were the deep conversations with key opinion leaders: ⭐️John Crothers (President of Pathology Australia & CEO of RCPA QAP) emphasized URIT’s unique advantage in total quality control. Unlike standalone analyzers, our flow cytometer with integrated pre-analytical processing "solidifies sample preparation"—the most variable step—into the hardware itself. He sees this as a closed-loop system that inherently reduces inter-laboratory deviation, a critical need for his EQA programs.⭐️Dr. Olga Pozdnyakova (Director of Hematopathology at UPenn) expressed keen interest in how our automated pre-processing addresses her "quartet of pain points"—quality, data, efficiency, and compliance. For her, a standardized platform is the key to training AI models and ensuring data uniformity across multi-center trials.
Better Health For All isn't just our mission—it’s our commitment. See you at the URIT booth for a live demo of our track systems and automation solutions.💞
 |
